PTO/SB/08b (03-09)
Approved for use through 04/30/2009, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/551,643-Conf. #5446	
INFORMATION DISCLOSURE				Filing Date	July 24, 2006	
STATEMENT BY APPLICANT (Use as many sheets as necessary)			APPLICANT	First Named Inventor	Giovanni Monteleone	
				Art Unit	1635	
			necessary)	Examiner Name	K. Chong	
Sheet	1	of	2	Attorney Docket Number	GIU-001	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A2*	US-6,020,464	02-01-2000	Okazaki et al.	
	A3*	US-6,747,014	06-08-2004	Teng et al.	
	A4*	US-20020147140	10-10-2002	Rosen et al.	
	A5*	US-20020061569	05-23-2002	Haselbeck et al.	
	A6*	US-20040209805	10-21-2004	Phillips et al.	
	A7*	US-20040265833	12-30-2004	Lofton-Day et al.	
	A8*	US-20060034800	02-16-2006	Sanna et al.	
	A9*	US-20070167385	07-19-2007	Monteleone	
	A10*	US-20080214483	09-04-2008	Schlingensiepen et al.	

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>ii known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	 T'
	B3	EP-874046	10-28-1998	Biomolecular Engineering	3	一
	B4	EP-1308459	05-07-2003	Helix Res Inst [JP] et al.		H
	B5	WO-97/30065	08-21-1997	Millennium Pharm Inc.		-
	B6	WO-98/53068	11-26-1998	Ludwig Inst Cancer Res		-
	B7	WO-99/50296 02/068579	09-06-2002	PE Corp NY US		H
	B8	WO-99/60012	11-25-1999	Isis Pharmaceuticals		┢
	B9	WO-00/06206	02-10-2000	Millennium Pharm Inc.		-
	B10	WO-01/94629	12-13-2001	Avalon Pharmaceuticals		┢
	B11	WO-01/57182	08-09-2001	Human Genome Sciences Inc. et al.		
	B12	WO-01/55367	08-02-2001	Human Genome Sciences Inc. et al.		
	B13	WO-02/00927	01-03-2002	Epigenomics AG		
	B14	WO-02/68579	09-06-2002	PE Corp NY US		
	B15	WO-02/12440	02-14-2002	Gene Logic [US] et al.		
	B16	WO-02/77183	10-03-2002	Elitra Pharmaceuticals et al.		
	B17	WO-02/85285	10-31-2002	Wyeth Corp et al.		
-	B18	WO-03/37368	05-08-2003	Steinbrecher Andreas [DE] et al.		
	B19	WO-04/87920	10-14-2004	Giuliani Spa [IT] et al.		Г
	B20	WO-04/83389	09-30-2004	Exelixis Inc. et al.		
-	B21	WO-04/41170	05-21-2004	Genentech Inc. et al.		
-	B22	WO-04/53099	06-24-2004	Scripps Research Inst et al.		
	B23	WO-05/98041	10-20-2005	University of Florida et al.		

Examiner	Date	
Signature	Consid	ered